Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.51 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.51 |
| ▸ | XBP1 | P17861 | 1/20 | 0.51 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | MITF | O75030 | 1/20 | 0.48 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.48 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.47 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | TNKS | O95271 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6097459 | 0.83 | S100A4 (0.47) | ALDH1A1MAPTNPSR1RAB9ANPC1 | |
| SCHEMBL6099876 | 0.83 | LMNA (0.40) | ALDH1A1MAPTNPSR1RAB9ANPC1 | |
| SCHEMBL1895900 | 0.83 | MAPT (0.36) | ALDH1A1MAPTNPSR1RAB9ANPC1 | |
| Water SCHEMBL6101423 | 0.82 | S100A4 (0.46) | ALDH1A1MAPTNPSR1RAB9ANPC1 | |
| SCHEMBL4302874 | 0.81 | ALDH1A1 (0.39) | ALDH1A1MAPTNPSR1RAB9ANPC1 | |
| SCHEMBL6100932 | 0.79 | S100A4 (0.34) | ALDH1A1MAPTNPSR1RAB9ANPC1 | |
| SCHEMBL6100934 | 0.79 | S100A4 (0.34) | ALDH1A1MAPTNPSR1RAB9ANPC1 | |
| SCHEMBL6100506 | 0.77 | MAPT (0.47) | ALDH1A1MAPTNPSR1RAB9ANPC1 | |
| SCHEMBL6099648 | 0.74 | ALDH1A1 (0.45) | ALDH1A1MAPTNPSR1LMNAHTT | |
| SCHEMBL8637191 | 0.74 | MAPT (0.36) | ALDH1A1MAPTNPSR1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6989389-B2 | Aryl ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES CO. (US) | 2006-01-24 | — | — | US | disclosed |
| US-6953804-B2 | Aryl ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES CO. (US) | 2005-10-11 | — | — | US | disclosed |
| US-20040138248-A1 | Aryl ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-07-15 | — | — | US | disclosed |
| US-20040106640-A1 | Aryl ether substituted imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. | 2004-06-03 | — | — | US | disclosed |
| US-20040072858-A1 | Heterocyclic ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-04-15 | — | — | US | disclosed |
| US-6677348-B2 | INDUCE CYTOKINE BIOSYNTHESIS; ANTICARCINOGENIC AGENTS, VIRICIDES | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-13 | — | — | US | disclosed |
| US-6670372-B2 | Immunomodulators, for inducing cytokine biosynthesis in animals, and in the treatment of viral and neoplastic diseases; imidazo(4,5-c) quinoline-4-amine compounds that have an ether containing substituent at the 1-position | 3M INNOVATIVE PROPERTIES COMPANY | 2003-12-30 | — | — | US | disclosed |
| US-6664260-B2 | Viricides; anticarcinogneic agents; induction cytokine biosynthesis | 3M INNOVATIVE PROPERTIES COMPANY | 2003-12-16 | — | — | US | disclosed |
| US-20030212092-A1 | Aryl ether substituted imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. | 2003-11-13 | — | — | US | disclosed |
| US-20030212091-A1 | Aryl ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-11-13 | — | — | US | disclosed |
| EP-1341789-A2 | ARYL ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2003-09-10 | — | — | EP | disclosed |
| EP-1339715-A2 | HETEROCYCLIC ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20030065005-A1 | Heterocyclic ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-04-03 | — | — | US | disclosed |
| WO-2002046193-A2 | HETEROCYCLIC ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
| WO-2002046189-A2 | ARYL ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065005-A1 | Heterocyclic ether substituted imidazoquinolines | IFNG, IL2, IRF3 | ALDH1A1 2486/4885MAPT 4130/4885NPSR1 4094/4885 |
| US-20040138248-A1 | Aryl ether substituted imidazoquinolines | IRF3, IFNG, MYD88 | ALDH1A1 1364/4885MAPT 3670/4885NPSR1 4329/4885 |
| US-20040106640-A1 | Aryl ether substituted imidazoquinolines | IRF3, IFNG, MYD88 | ALDH1A1 1364/4885MAPT 3670/4885NPSR1 4329/4885 |
| US-20030212092-A1 | Aryl ether substituted imidazoquinolines | IRF3, IFNG, MYD88 | ALDH1A1 1364/4885MAPT 3670/4885NPSR1 4329/4885 |
| US-20030212091-A1 | Aryl ether substituted imidazoquinolines | IRF3, IFNG, MYD88 | ALDH1A1 1364/4885MAPT 3670/4885NPSR1 4329/4885 |
| US-20040072858-A1 | Heterocyclic ether substituted imidazoquinolines | IFNG, IL2, IRF3 | ALDH1A1 2486/4885MAPT 4130/4885NPSR1 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.